% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • justarook04 justarook04 Feb 11, 2014 5:35 PM Flag

    The Wedbush Analyst was Gregory Wade and he feels that a PH III trial will be needed per data reviewed.

    Again, tell me someone HOW does he know? The PH II trial has insufficient data per Wedbush's review. HOW did they get to review the data?

    Now if this actually occurs in the future, Wedbush is guilty of leaking info to the market.

    "Wedbush's Gregory R. Wade has downgraded Insmed (INSM -10.9%) to Underperform, and cut his PT all the way to $7 from $18.
    Wade states Wedbush's review of an Insmed Phase II study for its Arikace drug suggests "there will be insufficient data" for the FDA to approve using it to treat nontuberculous mycobacteria (NTM) lung infections. The firm now thinks a Phase III study will be needed, something it doesn't believe is priced into shares."

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
9.72+0.67(+7.40%)Jun 28 4:00 PMEDT